These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8025286)

  • 1. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia.
    Tari AM; Tucker SD; Deisseroth A; Lopez-Berestein G
    Blood; 1994 Jul; 84(2):601-7. PubMed ID: 8025286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal delivery of oligodeoxynucleotides.
    Tari A; Khodadadian M; Ellerson D; Deisseroth A; Lopez-Berestein G
    Leuk Lymphoma; 1996 Mar; 21(1-2):93-7. PubMed ID: 8907275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Verfaillie CM
    Blood; 1998 May; 91(9):3414-22. PubMed ID: 9558400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
    Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
    J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
    Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
    Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
    Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
    Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
    Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
    Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
    Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
    Smetsers TF; Linders EH; van de Locht LT; de Witte TM; Mensink EJ
    Br J Haematol; 1997 Feb; 96(2):377-81. PubMed ID: 9029029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
    Rapozzi V; Cogoi S; Xodo LE
    Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
    Martiat P; Lewalle P; Taj AS; Philippe M; Larondelle Y; Vaerman JL; Wildmann C; Goldman JM; Michaux JL
    Blood; 1993 Jan; 81(2):502-9. PubMed ID: 8422466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM
    Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
    Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
    Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
    Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.